Denied Wearable Defibrillator Appeals: Outcomes

A wearable defibrillator vest prescribed for a defined period of elevated arrhythmic risk — typically after myocardial infarction, during a bridge to an implantable device, or while ejection fraction is expected to recover.

What the independent reviewers decided

64%

overturned by the independent reviewer

of 53 decisions in the corpus

Source

California DMHC independent medical review determinations, 2017-2026. Public record.

Read this as a base rate, not as your odds

These are decisions about other patients, in one state, that had already been through the plan's own internal appeal and were then sent to an outside reviewer. That population is self-selected toward disputes worth pursuing, so the rate says what happened to cases like this at that stage — not what will happen to a specific claim. It is not medical or legal advice.

Why plans deny wearable cardioverter defibrillator

The policy covers the device only for enumerated indications and the submitted one is outside them.
The ejection fraction or the interval since the qualifying event does not meet the criteria.
The plan holds that an implantable device should be placed instead.
Continuation past the policy's period is denied without a repeat assessment.

What actually carried the cases that won

Guideline support appeared in 88% of the reversals and clinical guidelines were the cited authority in 79% — the strongest single concentration anywhere in this corpus, with specialty-society criteria at 44% behind them. This is a decision space governed almost entirely by published cardiology criteria, which is good news for an appeal: name the recommendation, state the ejection fraction and the date of the qualifying event, and the argument is largely made. Diagnostic confirmation at 44% reflects how often the underlying measurement was the contested fact.

What the record showed	Share of overturned decisions
A published guideline supported the request	88%
The severity or urgency was documented	62%
The diagnosis was confirmed	44%
The condition was documented as chronic or long-standing	12%
Conservative treatment was documented as failed	3%
Prior treatment was documented	3%
Objective findings were documented	3%

Shares are of the overturned decisions and do not sum to 100% — a single decision often rested on more than one, and some rested on none of these.

What the reviewers cited

Clinical guidelines — in 79% of the overturned decisions
Specialty-society criteria — in 44% of the overturned decisions
Peer-reviewed literature — in 38% of the overturned decisions
Standard of care — in 3% of the overturned decisions

wearable cardioverter defibrillator denials — frequently asked

Is a denied wearable defibrillator worth appealing?

Close to two thirds fell — 34 reversals across 53 California determinations.

What is the strongest argument?

A published recommendation the patient meets. Guideline support was present in 88% of the reversals and clinical guidelines were cited in 79% — a concentration that appears nowhere else in this corpus.

How is a continuation request handled?

With a repeat measurement. Where the policy sets a period tied to expected recovery, the reversals supplied the current ejection fraction and the reassessment rather than asking for an extension on the original basis.

Source

California Department of Managed Health Care — independent medical review determinations

Denial reasons and criteria are described in plain language for reference and vary by plan and policy. This page reports what independent reviewers decided in a public California dataset; it is general information, not medical, legal, or coverage advice.

When the appeal has to be written, and cited

Upload the denied EOB and Merits returns a complete, citation-verified appeal letter — the clinical argument, the payer's own coverage criteria, and your federal appeal rights — in about a minute.

Appeal a denial →